Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Sanofi will take the lead co-commercialization role for ... give this vaccine candidate the highest probability of success ...
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
Notably, the eczema and asthma treatment from Sanofi and Regeneron nearly doubled the national ... Haleon’s Robitussin and ...
Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...
The shift to a clear recommendation for vaccination goes beyond the prior guidance "just to encourage adults to talk to their ...
Sanofi Korea Corporation (hereinafter referred to as Sanofi) successfully concluded the RSV story contest\ for parents who ...
Sanofi and AZ have been working hard to lay ... An alternative to the antibody therapies is Pfizer's RSV vaccine Abrysvo, which is approved for maternal immunisation to prevent disease in newborns ...
A Winnipeg mother with a newborn is pleading with the province to start offering RSV shots to all babies. As we navigate ...